NEW YORK, NY / ACCESSWIRE / October 21, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Anaplan Inc. (NYSE:PLAN)
Class Period: November 21, 2019 - February 26, 2020
Lead Plaintiff Deadline: October 23, 2020
The complaint alleges that throughout the class period Anaplan Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was undergoing sales organization and execution challenges; (2) these organizational challenges were causing the Company to miss on closing very important large deals; and (3) as a result, Anaplan's financial guidance for "calculated billings growth" was baseless and unattainable. Further, while in possession of this material non-public information, Anaplan insiders dumped approximately $30 million worth of Anaplan stock at artificially inflated prices.
Learn about your recoverable losses in PLAN: http://www.kleinstocklaw.com/pslra-1/anaplan-inc-loss-submission-form?id=10351&from=1
Nano-X Imaging Ltd. (NASDAQ:NNOX)
Class Period: August 21, 2020 - September 15, 2020
Lead Plaintiff Deadline: November 16, 2020
The complaint alleges Nano-X Imaging Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) Nano-X's commercial agreements and its customers were fabricated; (2) Nano-X's statements regarding its "novel" Nanox System were misleading as the Company never provided data comparing its images with images from competitors' machines; (3) Nano-X's submission to the U.S. Food and Drug Administration admitted the Nanox System was not original; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Learn about your recoverable losses in NNOX: http://www.kleinstocklaw.com/pslra-1/nano-x-imaging-ltd-loss-submission-form?id=10351&from=1
Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
Class Period: October 15, 2019 - August 7, 2020
Lead Plaintiff Deadline: December 14, 2020
The complaint alleges that throughout the class period, Reata Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (ii) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in RETA: http://www.kleinstocklaw.com/pslra-1/reata-pharmaceuticals-inc-loss-submission-form?id=10351&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899, or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm